Copyright Reports & Markets. All rights reserved.

Global Digital Biomarker Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Digital Biomarker by Type
    • 1.3.1 Overview: Global Digital Biomarker Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Digital Biomarker Consumption Value Market Share by Type in 2025
    • 1.3.3 Passive Digital Biomarker
    • 1.3.4 Active Digital Biomarker
  • 1.4 Global Digital Biomarker Market by Application
    • 1.4.1 Overview: Global Digital Biomarker Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Clinical Disease
    • 1.4.3 Daily Health
  • 1.5 Global Digital Biomarker Market Size & Forecast
  • 1.6 Global Digital Biomarker Market Size and Forecast by Region
    • 1.6.1 Global Digital Biomarker Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Digital Biomarker Market Size by Region, (2021-2032)
    • 1.6.3 North America Digital Biomarker Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Digital Biomarker Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Digital Biomarker Market Size and Prospect (2021-2032)
    • 1.6.6 South America Digital Biomarker Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Digital Biomarker Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Philips
    • 2.1.1 Philips Details
    • 2.1.2 Philips Major Business
    • 2.1.3 Philips Digital Biomarker Product and Solutions
    • 2.1.4 Philips Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Philips Recent Developments and Future Plans
  • 2.2 Johnson & Johnson
    • 2.2.1 Johnson & Johnson Details
    • 2.2.2 Johnson & Johnson Major Business
    • 2.2.3 Johnson & Johnson Digital Biomarker Product and Solutions
    • 2.2.4 Johnson & Johnson Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Digital Biomarker Product and Solutions
    • 2.3.4 Pfizer Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Pfizer Recent Developments and Future Plans
  • 2.4 GE Healthcare
    • 2.4.1 GE Healthcare Details
    • 2.4.2 GE Healthcare Major Business
    • 2.4.3 GE Healthcare Digital Biomarker Product and Solutions
    • 2.4.4 GE Healthcare Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GE Healthcare Recent Developments and Future Plans
  • 2.5 Novartis
    • 2.5.1 Novartis Details
    • 2.5.2 Novartis Major Business
    • 2.5.3 Novartis Digital Biomarker Product and Solutions
    • 2.5.4 Novartis Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Novartis Recent Developments and Future Plans
  • 2.6 Apple
    • 2.6.1 Apple Details
    • 2.6.2 Apple Major Business
    • 2.6.3 Apple Digital Biomarker Product and Solutions
    • 2.6.4 Apple Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Apple Recent Developments and Future Plans
  • 2.7 Sanofi
    • 2.7.1 Sanofi Details
    • 2.7.2 Sanofi Major Business
    • 2.7.3 Sanofi Digital Biomarker Product and Solutions
    • 2.7.4 Sanofi Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sanofi Recent Developments and Future Plans
  • 2.8 GlaxoSmithKline
    • 2.8.1 GlaxoSmithKline Details
    • 2.8.2 GlaxoSmithKline Major Business
    • 2.8.3 GlaxoSmithKline Digital Biomarker Product and Solutions
    • 2.8.4 GlaxoSmithKline Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 GlaxoSmithKline Recent Developments and Future Plans
  • 2.9 Bayer
    • 2.9.1 Bayer Details
    • 2.9.2 Bayer Major Business
    • 2.9.3 Bayer Digital Biomarker Product and Solutions
    • 2.9.4 Bayer Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Bayer Recent Developments and Future Plans
  • 2.10 Merck
    • 2.10.1 Merck Details
    • 2.10.2 Merck Major Business
    • 2.10.3 Merck Digital Biomarker Product and Solutions
    • 2.10.4 Merck Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Merck Recent Developments and Future Plans
  • 2.11 Abbott Laboratories
    • 2.11.1 Abbott Laboratories Details
    • 2.11.2 Abbott Laboratories Major Business
    • 2.11.3 Abbott Laboratories Digital Biomarker Product and Solutions
    • 2.11.4 Abbott Laboratories Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Abbott Laboratories Recent Developments and Future Plans
  • 2.12 Asahi Kasei
    • 2.12.1 Asahi Kasei Details
    • 2.12.2 Asahi Kasei Major Business
    • 2.12.3 Asahi Kasei Digital Biomarker Product and Solutions
    • 2.12.4 Asahi Kasei Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Asahi Kasei Recent Developments and Future Plans
  • 2.13 Biogen
    • 2.13.1 Biogen Details
    • 2.13.2 Biogen Major Business
    • 2.13.3 Biogen Digital Biomarker Product and Solutions
    • 2.13.4 Biogen Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Biogen Recent Developments and Future Plans
  • 2.14 Koneksa Health
    • 2.14.1 Koneksa Health Details
    • 2.14.2 Koneksa Health Major Business
    • 2.14.3 Koneksa Health Digital Biomarker Product and Solutions
    • 2.14.4 Koneksa Health Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Koneksa Health Recent Developments and Future Plans
  • 2.15 Roche
    • 2.15.1 Roche Details
    • 2.15.2 Roche Major Business
    • 2.15.3 Roche Digital Biomarker Product and Solutions
    • 2.15.4 Roche Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Roche Recent Developments and Future Plans
  • 2.16 Huma Therapeutics
    • 2.16.1 Huma Therapeutics Details
    • 2.16.2 Huma Therapeutics Major Business
    • 2.16.3 Huma Therapeutics Digital Biomarker Product and Solutions
    • 2.16.4 Huma Therapeutics Digital Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Huma Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Digital Biomarker Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Digital Biomarker by Company Revenue
    • 3.2.2 Top 3 Digital Biomarker Players Market Share in 2025
    • 3.2.3 Top 6 Digital Biomarker Players Market Share in 2025
  • 3.3 Digital Biomarker Market: Overall Company Footprint Analysis
    • 3.3.1 Digital Biomarker Market: Region Footprint
    • 3.3.2 Digital Biomarker Market: Company Product Type Footprint
    • 3.3.3 Digital Biomarker Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Digital Biomarker Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Digital Biomarker Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Digital Biomarker Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Digital Biomarker Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Digital Biomarker Consumption Value by Type (2021-2032)
  • 6.2 North America Digital Biomarker Market Size by Application (2021-2032)
  • 6.3 North America Digital Biomarker Market Size by Country
    • 6.3.1 North America Digital Biomarker Consumption Value by Country (2021-2032)
    • 6.3.2 United States Digital Biomarker Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Digital Biomarker Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Digital Biomarker Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Digital Biomarker Consumption Value by Type (2021-2032)
  • 7.2 Europe Digital Biomarker Consumption Value by Application (2021-2032)
  • 7.3 Europe Digital Biomarker Market Size by Country
    • 7.3.1 Europe Digital Biomarker Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Digital Biomarker Market Size and Forecast (2021-2032)
    • 7.3.3 France Digital Biomarker Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Digital Biomarker Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Digital Biomarker Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Digital Biomarker Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Digital Biomarker Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Digital Biomarker Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Digital Biomarker Market Size by Region
    • 8.3.1 Asia-Pacific Digital Biomarker Consumption Value by Region (2021-2032)
    • 8.3.2 China Digital Biomarker Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Digital Biomarker Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Digital Biomarker Market Size and Forecast (2021-2032)
    • 8.3.5 India Digital Biomarker Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Digital Biomarker Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Digital Biomarker Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Digital Biomarker Consumption Value by Type (2021-2032)
  • 9.2 South America Digital Biomarker Consumption Value by Application (2021-2032)
  • 9.3 South America Digital Biomarker Market Size by Country
    • 9.3.1 South America Digital Biomarker Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Digital Biomarker Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Digital Biomarker Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Digital Biomarker Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Digital Biomarker Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Digital Biomarker Market Size by Country
    • 10.3.1 Middle East & Africa Digital Biomarker Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Digital Biomarker Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Digital Biomarker Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Digital Biomarker Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Digital Biomarker Market Drivers
  • 11.2 Digital Biomarker Market Restraints
  • 11.3 Digital Biomarker Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Digital Biomarker Industry Chain
  • 12.2 Digital Biomarker Upstream Analysis
  • 12.3 Digital Biomarker Midstream Analysis
  • 12.4 Digital Biomarker Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Digital Biomarker market size was valued at US$ 3724 million in 2025 and is forecast to a readjusted size of US$ 225140 million by 2032 with a CAGR of 80.6% during review period.
    Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables, or digestibles. The data collected are typically used to explain, influence, and/or predict health-related outcomes. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data.
    Digital biomarkers refer to biomedical data collected and analyzed through digital technology, which are used to detect, monitor and predict disease biomarkers. These data are usually collected through technologies such as smart devices, wearable sensors, and mobile applications, including physiological data such as heart rate, gait, blood sugar, brain waves, and sleep patterns. In recent years, with the rapid development of technologies such as artificial intelligence, big data analysis, and the Internet of Things (IoT), digital biomarkers have gradually shown great potential in disease diagnosis, efficacy evaluation, and health management.
    At present, the digital biomarker market is in a rapid development stage. The popularity of digital health devices and the demand for personalized medicine and precision medicine have promoted the research and application of digital biomarkers. In the early diagnosis and monitoring of some chronic disease management and neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), digital biomarkers have shown significant application value. In addition, digital biomarkers are also playing an increasingly important role in the drug development process, especially in the recruitment of patients in clinical trials, monitoring of treatment effects, and evaluation of side effects.
    In the future, digital biomarkers are expected to be more widely used in multiple fields. First, with the continuous advancement of artificial intelligence and machine learning algorithms, the analytical capabilities of digital biomarkers will become more accurate and efficient, which will help to formulate more personalized treatment plans. Secondly, with the popularization of 5G technology, the improvement of real-time data transmission capabilities will enable digital biomarkers to monitor patients' health status in real time and increase the possibility of early detection of diseases. In addition, cross-industry cooperation and standardization of digital biomarkers will also promote their widespread application around the world.
    Philips and Novartis are the top 2 companies in global digital biomarker market and account for over 15% of total market share. Geographically speaking, Europe holds about 45% of global market share, followed by North America with about 35% share. In terms of type, passive digital biomarker segment holds an important share of about 65%. In terms of application, clinical disease segment accounts for about 80% of the total share.
    This report is a detailed and comprehensive analysis for global Digital Biomarker market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Digital Biomarker market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Digital Biomarker market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Digital Biomarker market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Digital Biomarker market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Digital Biomarker
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Digital Biomarker market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Philips, Johnson & Johnson, Pfizer, GE Healthcare, Novartis, Apple, Sanofi, GlaxoSmithKline, Bayer, Merck, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Digital Biomarker market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Passive Digital Biomarker
    Active Digital Biomarker
    Market segment by Application
    Clinical Disease
    Daily Health
    Market segment by players, this report covers
    Philips
    Johnson & Johnson
    Pfizer
    GE Healthcare
    Novartis
    Apple
    Sanofi
    GlaxoSmithKline
    Bayer
    Merck
    Abbott Laboratories
    Asahi Kasei
    Biogen
    Koneksa Health
    Roche
    Huma Therapeutics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Digital Biomarker product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Digital Biomarker, with revenue, gross margin, and global market share of Digital Biomarker from 2021 to 2026.
    Chapter 3, the Digital Biomarker competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Digital Biomarker market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Digital Biomarker.
    Chapter 13, to describe Digital Biomarker research findings and conclusion.

    Buy now